Episodes

  • Innovations in GERD: What Vonoprazan (Voquezna) May Offer Over PPIs, with Adelina Hung, MD

    Innovations in GERD: What Vonoprazan (Voquezna) May Offer Over PPIs, with Adelina Hung, MD
    Jul 18 2024
    Proton pump inhibitors have long been the mainstay of treatment for gastroesophageal reflux disease (GERD), dating back to omeprazole (Prilosec)’s initial approval in 1989. However, the treatment landscape has undergone its first major changes in the past 30 years with the emergence of vonoprazan (Voquezna).

    A novel, first-in-class small molecule potassium-competitive acid blocker (PCAB), vonoprazan now boasts 3 US Food and Drug Administration (FDA) approvals across both erosive and non-erosive GERD. Less than a year after earning approval for the healing and maintenance of healing of all grades of erosive GERD as well as the relief of heartburn associated with erosive GERD, vonoprazan has also been approved for the treatment of heartburn in non-erosive GERD.
    Show more Show less
    7 mins
  • FDA First Half Recap: Dermatology in 2024

    FDA First Half Recap: Dermatology in 2024
    Jul 3 2024
    Led by a flood of biologic therapies becoming available and progressing within the therapeutic pipeline, the field of dermatology finds itself in the midst of a watershed moment for many dermatologic conditions. To celebrate and recap the advancements occurring in the first half of 2024, the editorial team of HCPLive Dermatology sat down with James Del Rosso, DO, research director of JDR Dermatology Research and president of the American Acne and Rosacea Society, for more perspective on pipeline movement.

    Del Rosso, who also serves as an adjunct clinical professor of Dermatology at Touro University, takes a deep dive into several different disease states in dermatology and highlights how the news to emerge in the last 6 months, as well as prior to the close of 2023, has influenced real-world management.
    Show more Show less
    40 mins
  • New Insight: A Look at Gildeuretinol (ALK-001) for Stargardt Disease w/ Seemi Khan, MD

    New Insight: A Look at Gildeuretinol (ALK-001) for Stargardt Disease w/ Seemi Khan, MD
    Jul 2 2024
    In the latest episode of New Insight with Veeral Sheth, MD, host Veeral Sheth, MD, director of clinical research at University Retina, speaks with Seemi Khan, chief medical officer at Alkeus Pharmaceuticals, on the company’s lead candidate being evaluated in clinical trials for the treatment of Stargardt disease and geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

    Gildeuretinol is a novel molecule designed as a specialized form of deuterated vitamin A to reduce the dimerization of vitamin A without disrupting vision. The therapy has received Breakthrough and Orphan Drug designations from the US Food and Drug Administration (FDA).

    Listen to the conversation between experts on Khan’s background in the pharmaceutical industry, including time spent at Abbott, Abbvie, and Quark Pharmaceuticals, her experience bringing treatments to patients with rare diseases, and the impressive data from gildeuretinol in the TEASE clinical trial program for a currently unmet need.

    Episode Highlights
    0:07     Episode Intro
    0:57 Seemi Khan's background
    4:38 Mechanism of action of gildeuretinol
    7:22 Patient populations
    9:00 TEASE clinical trial program
    14:37 Gildeuretinol in GA
    16:32 Safety data
    18:47 Next steps for Alkeus
    22:28 Conclusion

    Check out more ophthalmology coverage at HCPLive.com!
    Show more Show less
    21 mins
  • New Insight: A Look at the OcuLenz with Michael Freeman, CEO of Ocutrx

    New Insight: A Look at the OcuLenz with Michael Freeman, CEO of Ocutrx
    Jun 11 2024
    Since the mid-20th century ushered in the ‘Information Age’, a desire for innovation has driven the pursuit of technological advancements. Many may immediately consider the transformations personal computers and smartphones have had on modern society, but these advancements have transformed the fields of medicine time and time again.

    In the latest episode of New Insight with Veeral Sheth, MD, Michael Freeman, the chief executive officer of Ocutrx, joins Dr. Sheth to discuss the history of Ocutrx, its OcuLez and OR-Bot products, and what he envisions in the next decade at the company.

    Episode Highlights
    0:06 Introduction
    1:22 History of Ocutrx
    9:05 A look at the Oculenz
    18:27 Introduction of a caretaker app
    19:26 A look at the OR-Bot
    25:55 Envisioning the next decade at Ocutrx
    29:02 Conclusion

    Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at ciapoce@mjhlifesciences.com.
    Show more Show less
    29 mins
  • Andrew F. Alexis, MD, MPH: Discussing Controversies in Acne, Rosacea

    Andrew F. Alexis, MD, MPH: Discussing Controversies in Acne, Rosacea
    Mar 14 2024
    Episode Highlights:

    0:16 Intro

    0:28 Overview of presentation

    0:38 Acne and post-inflammatory hyperpigmentation

    01:35 Approaches to take

    03:21 Rosacea, use of dermoscopy and symptomatology assessment

    04:59 Necessity of inclusivity in clinical trials, other knowledge gaps

    06:05 Images used in education


    The American Academy of Dermatology (AAD) Annual Meeting in 2024 featured Dr. Andrew Alexis, a prominent figure in dermatology. Dr. Alexis, currently serving as the vice-chair for diversity in the department of dermatology and a professor of clinical dermatology at Weill Cornell Medical College in New York, presented a talk titled "Controversies in Acne and Rosacea."


    In the interview, he shed light on critical aspects of managing acne and rosacea, particularly focusing on patients with skin of color.


    Dr. Alexis advocated for inclusivity in clinical trials to improve understanding across diverse patient populations. He stressed the importance of expanding public awareness of rosacea in communities with skin of color and suggested incorporating diverse images into educational materials to better represent the spectrum of affected individuals.


    Dr. Alexis's insights underscore the necessity of tailored approaches and increased inclusivity in dermatological research and education to better serve patients with diverse skin tones and backgrounds.


    For additional information covered at the 2024 AAD conference, visit us at: https://www.hcplive.com/conference/aad.
    Show more Show less
    9 mins
  • New Insight: Role of Contract Research Organizations in Retina w/ Brad Doerschuk

    New Insight: Role of Contract Research Organizations in Retina w/ Brad Doerschuk
    Feb 29 2024
    In the medical community, a revolving cast of players plays a pivotal role in advancing scientific discovery and enhancing patient outcomes. During the research stage, a collaborative team effort, from the clinical trial sponsors to research sites and patient populations, is essential to ensure smooth progress and sustain momentum toward the finish line.

    The latest episode of New Insight with Veeral Sheth, MD features a conversation with Brad Doerschuk, the CEO of InFocus Clinical Research, on the important role of contract research organizations (CROs) in retina and the field of ophthalmology.

    In their conversation, Sheth and Doerschuk shed light on the role of CROs in managing clinical trials, dive into the evolution of the retina space in recent decades, and describe the challenges in recruiting for trials of new agents.

    Episode Highlights
    0:00 Introduction
    0:52 What is a CRO?
    2:13 Development of InFocus
    6:45 Discussing the retina pipeline
    11:46 Recruitment challenges, solutions
    15:50 Developing new clinical trial sites
    18:19 Relationship between investigators, CROs
    19:56 Shift in FDA guidance
    23:14 New trial endpoints
    25:16 Conclusion

    Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at ciapoce@mjhlifesciences.com.
    Show more Show less
    30 mins
  • New Insight: Reengaging the Retina Community in 2024 w/ David Eichenbaum, MD and Roger Goldberg, MD

    New Insight: Reengaging the Retina Community in 2024 w/ David Eichenbaum, MD and Roger Goldberg, MD
    Feb 12 2024
    A special double-episode of New Insight with Veeral Sheth, MD features a well-rounded conversation on all things ophthalmology with returning guest David Eichenbaum, MD, the director of research for Retina Vitreous Associates of Florida, as well as first-time guest Roger Goldberg, MD, a vitreoretinal surgeon at Bay Area Retina Associates.

    The trio of retina specialists discuss recent conference news, the anniversary of a landmark agent, and what’s to come in 2024 for the specialty.

    Episode Highlights:
    0:00 Introduction
    1:25 Entering 2024
    7:34 The importance of treatment efficacy
    12:09 Re-engaging GA treatment
    15:05 Comparing aflibercept 8 mg and faricimab
    23:00 Real-world data sets
    26:30 What’s to come in 2024
    27:45 Intravitreal gene therapies
    31:00 Port delivery system
    36:00 Wrapping-up 

    Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at ciapoce@mjhlifesciences.com.
    Show more Show less
    40 mins
  • New Insight: A Look at APX3330 for Diabetic Retinopathy with George Magrath, MD

    New Insight: A Look at APX3330 for Diabetic Retinopathy with George Magrath, MD
    Dec 18 2023
    In every episode of New Insight, Veeral Sheth, MD, Director of Clinical Trials at University Retina in Chicago, takes an in-depth look at the biggest news in ophthalmology and the behind the scenes work involved in eye care, with a rotation of guest experts involved in ophthalmic research, development, and clinical care.

    The latest episode of New Insight features a conversation with Ocuphire Pharma’s CEO on the company’s flagship retinal product and leading a small, but high-powered research team.

    Episode Highlights:
    0:04 Introduction
    1:23 History of Ocuphire Pharma
    3:50 Leading a small, high-functioning team
    6:41 Magrath’s background and journey
    11:02 APX3330 for Diabetic Retinopathy
    15:20 2024 Plans for Ocuphire
    18:53 Addressing unmet needs
    20:20 Outro

    Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at ciapoce@mjhlifesciences.com.
    Show more Show less
    22 mins